CNS depressant; may result in additive or potentiating effect with brimonidine on the central nervous system.
Source: NLP:brimonidine tartrate ophthalmic solution, 0.15%
Brimonidine Tartrate Ophthalmic Solution, 0.15% Interactions
Brand names: Brimonidine Tartrate Ophthalmic Solution, 0.15%
Route: Ophthalmic
Contraindications
4 CONTRAINDICATIONS • Neonates and infants (under the age of 2 years). ( 4.1 ) 4.1 Neonates and Infants (under the age of 2 years) Brimonidine tartrate ophthalmic solution is contraindicated in neonates and infants (under the age of 2 years). 4.2 Hypersensitivity Reactions Brimonidine tartrate ophthalmic solution is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past.
Pregnancy & Breastfeeding
8.1 Pregnancy Pregnancy Category B: Teratogenicity studies have been performed in animals. Brimonidine tartrate was not teratogenic when given orally during gestation days 6 through 15 in rats and days 6 through 18 in rabbits. The highest doses of brimonidine tartrate in rats (2.5 mg/kg/day) and rabbits (5.0 mg/kg/day) achieved AUC exposure values 360- and 20-fold higher, or 260- and 15-fold higher, respectively, than similar values estimated in humans treated with brimonidine tartrate ophthalmic solution 0.15%,1 drop in both eyes three times daily. There are no adequate and well-controlled studies in pregnant women; however, in animal studies,brimonidine crossed the placenta and entered into the fetal circulation to a limited extent. Because animal reproduction studies are not always predictive of human response, brimonidine tartrate ophthalmic solution should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.
6 interactions on record
CNS depressant; may result in additive or potentiating effect with brimonidine on the central nervous system.
Source: NLP:brimonidine tartrate ophthalmic solution, 0.15%
Brimonidine may reduce blood pressure; caution is advised when used with cardiac glycosides due to potential additive hypotensive effects.
Source: NLP:brimonidine tartrate ophthalmic solution, 0.15%
May interfere with brimonidine metabolism and potentially result in increased hypotension and systemic side effects; caution is advised.
Source: NLP:brimonidine tartrate ophthalmic solution, 0.15%
CNS depressant; may result in additive or potentiating effect with brimonidine on the central nervous system.
Source: NLP:brimonidine tartrate ophthalmic solution, 0.15%
CNS depressant; may result in additive or potentiating effect with brimonidine on the central nervous system.
Source: NLP:brimonidine tartrate ophthalmic solution, 0.15%